The use of the CB2 pathway as a target in obesity therapy would imply chronic neuronal activation, which, in turn, by increasing excitatory synaptic transmission, would facilitate peripheral anti-obesity effects. Here, CNR2 is linked to obesity due to melanocortin 4 receptor deficiency.